Literature DB >> 27567487

Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A.

L J Kay1, T K Smulders-Srinivasan1, M Soundararajan2.   

Abstract

The dual-specificity tyrosine (Y) phosphorylation-regulated kinase DYRK1A, also known as Down syndrome (DS) kinase, is a dosage-dependent signaling kinase that was originally shown to be highly expressed in DS patients as a consequence of trisomy 21. Although this was evident some time ago, it is only in recent investigations that the molecular roles of DYRK1A in a wide range of cellular processes are becoming increasingly apparent. Since initial knowledge on DYRK1A became evident through minibrain mnb, the Drosophila homolog of DYRK1A, this review will first summarize the scientific reports on minibrain and further expand on the well-established neuronal functions of mammalian and human DYRK1A. Recent investigations across the current decade have provided rather interesting and compelling evidence in establishing nonneuronal functions for DYRK1A, including its role in infection, immunity, cardiomyocyte biology, cancer, and cell cycle control. The latter part of this review will therefore focus in detail on the emerging nonneuronal functions of DYRK1A and summarize the regulatory role of DYRK1A in controlling Tau and α-synuclein. Finally, the emerging role of DYRK1A in Parkinson's disease will be outlined.
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiomyocyte; DYRK1A; Down syndrome; HAART therapy; Myeloproliferative disorders; Neurodegenerative disorders; Parkinson's disease; Tauopathies; α-Synuclein

Mesh:

Substances:

Year:  2016        PMID: 27567487     DOI: 10.1016/bs.apcsb.2016.07.001

Source DB:  PubMed          Journal:  Adv Protein Chem Struct Biol        ISSN: 1876-1623            Impact factor:   3.507


  14 in total

1.  DYRK1A interacts with histone acetyl transferase p300 and CBP and localizes to enhancers.

Authors:  Shanshan Li; Chu Xu; Yinkun Fu; Pin-Ji Lei; Yanhua Yao; Wanli Yang; Ying Zhang; Michael P Washburn; Laurence Florens; Manish Jaiswal; Min Wu; Man Mohan
Journal:  Nucleic Acids Res       Date:  2018-11-30       Impact factor: 16.971

2.  Overexpression of the DYRK1A Gene (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A) Induces Alterations of the Serotoninergic and Dopaminergic Processing in Murine Brain Tissues.

Authors:  Jacqueline London; Claude Rouch; Linh Chi Bui; Elodie Assayag; Benoit Souchet; Fabrice Daubigney; Hind Medjaoui; Serge Luquet; Christophe Magnan; Jean Maurice Delabar; Julien Dairou; Nathalie Janel
Journal:  Mol Neurobiol       Date:  2017-05-25       Impact factor: 5.590

3.  Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model.

Authors:  Mariko Sawa; Cassia Overk; Ann Becker; Dominique Derse; Ricardo Albay; Kim Weldy; Ahmad Salehi; Thomas G Beach; Eric Doran; Elizabeth Head; Y Eugene Yu; William C Mobley
Journal:  Alzheimers Dement       Date:  2021-11-10       Impact factor: 16.655

Review 4.  Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's Disease.

Authors:  Daniel J Colacurcio; Anna Pensalfini; Ying Jiang; Ralph A Nixon
Journal:  Free Radic Biol Med       Date:  2017-10-06       Impact factor: 7.376

5.  Why West? Comparisons of clinical, genetic and molecular features of infants with and without spasms.

Authors:  Anne T Berg; Samya Chakravorty; Sookyong Koh; Zachary M Grinspan; Renée A Shellhaas; Russell P Saneto; Elaine C Wirrell; Jason Coryell; Catherine J Chu; John R Mytinger; William D Gaillard; Ignacio Valencia; Kelly G Knupp; Tobias Loddenkemper; Joseph E Sullivan; Annapurna Poduri; John J Millichap; Cynthia Keator; Courtney Wusthoff; Nicole Ryan; William B Dobyns; Madhuri Hegde
Journal:  PLoS One       Date:  2018-03-08       Impact factor: 3.240

Review 6.  Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome.

Authors:  Anouchka P Laurent; Rishi S Kotecha; Sébastien Malinge
Journal:  Leukemia       Date:  2020-05-20       Impact factor: 11.528

7.  DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B.

Authors:  Mina Yousefelahiyeh; Jingyi Xu; Estibaliz Alvarado; Yang Yu; David Salven; Robert M Nissen
Journal:  PLoS One       Date:  2018-11-29       Impact factor: 3.240

8.  Upregulated Expression of MicroRNA-204-5p Leads to the Death of Dopaminergic Cells by Targeting DYRK1A-Mediated Apoptotic Signaling Cascade.

Authors:  Ching-Chi Chiu; Tu-Hsueh Yeh; Rou-Shayn Chen; Hua-Chien Chen; Ying-Zu Huang; Yi-Hsin Weng; Yi-Chuan Cheng; Yu-Chuan Liu; Ann-Joy Cheng; Ya-Ching Lu; Yu-Jie Chen; Yan-Wei Lin; Chia-Chen Hsu; Ying-Ling Chen; Chin-Song Lu; Hung-Li Wang
Journal:  Front Cell Neurosci       Date:  2019-09-13       Impact factor: 5.505

9.  K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR.

Authors:  Pengshan Zhang; Zhe Zhang; Yinkun Fu; Ying Zhang; Michael P Washburn; Laurence Florens; Min Wu; Chen Huang; Zhaoyuan Hou; Man Mohan
Journal:  Cell Death Dis       Date:  2021-06-11       Impact factor: 8.469

10.  Neuronal overexpression of Alzheimer's disease and Down's syndrome associated DYRK1A/minibrain gene alters motor decline, neurodegeneration and synaptic plasticity in Drosophila.

Authors:  Simon A Lowe; Maria M Usowicz; James J L Hodge
Journal:  Neurobiol Dis       Date:  2019-01-28       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.